Progress of targeting PI3K-AKT-mTOR signaling pathway inhibitors in treatment of triple-negative breast cancer

Peiyu LI; Fuguo TIAN.
Cancer Research and Clinic ; (6): 525-528, 2020.
Artículo en Zh | WPRIM | ID: wpr-872542

Documentos relacionados

  1. Biomedical research in france and brazil: an analysis of significant differences and ethical issues
  2. Progress of long non-coding RNA in treatment of triple-negative breast cancer
  3. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
  4. FUNDC2, a mitochondrial outer membrane protein, mediates triple-negative breast cancer progression via the AKT/GSK3ß/GLI1 pathway.
  5. Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.
  6. The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis.
  7. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
  8. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
  9. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.
  10. The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update.